Literature DB >> 2293976

Outpatient dobutamine for end-stage congestive heart failure.

L W Miller1, E J Merkle, V Herrmann.   

Abstract

Eleven patients with refractory class IV congestive heart failure who were not candidates for cardiac transplantation were given iv dobutamine therapy on an outpatient basis. All patients underwent hemodynamic evaluation to confirm a beneficial response to low dose (5 micrograms/kg.min) dobutamine and to establish arrhythmia control both on and off dobutamine before hospital discharge. Six of the 11 patients could not be weaned from dobutamine in hospital and were discharged on continuous infusion (maximum dose, 5 micrograms/kg.min), while four were discharged with an infusion regimen ranging from 3 to 5 consecutive days/wk. All patients had a chronic venous access placed and were instructed on the use of an external battery-powered infusion pump with a container holding a concentrated solution of dobutamine hydrochloride. All infusions were delivered at home on an ambulatory basis. Intravenous drug support was discontinued gradually over an average of 3.2 months; seven of 11 patients were able to be weaned entirely from iv inotropic therapy and were maintained on oral therapy alone. Seven of the 11 patients (six of whom were maintained on oral therapy alone) required no hospital readmission during the infusion or follow-up period.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293976

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Long-term dobutamine in heart failure.

Authors:  M Gorrie; A Nicholls
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

2.  Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial.

Authors:  Clyde W Yancy
Journal:  Heart Fail Rev       Date:  2004-07       Impact factor: 4.214

3.  Protocol for the implantation of a venous access device (Port-A-Cath System). The complications and solutions found in 560 cases.

Authors:  Luis Yeste Sánchez; José M Galbis Caravajal; Carlos A Fuster Diana; Enrique Moledo Eiras
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

Review 4.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Response to dobutamine and dopamine in the hypotensive very preterm infant.

Authors:  J C Rozé; C Tohier; C Maingueneau; M Lefèvre; A Mouzard
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

6.  Renal Function and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage Heart Failure: A Retrospective Single Center Study.

Authors:  Sean Verma; Emmanuel Bassily; Shane Leighton; Rahul Mhaskar; Igor Sunjic; Angel Martin; Nancy Rihana; Tambi Jarmi; Claude Bassil
Journal:  J Clin Med Res       Date:  2017-05-22

Review 7.  Inotropes do not increase mortality in advanced heart failure.

Authors:  Maya Guglin; Marc Kaufman
Journal:  Int J Gen Med       Date:  2014-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.